TENX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TENX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net margin is calculated as Net Income divided by its Revenue. Tenax Therapeutics's Net Income for the three months ended in Sep. 2024 was $-3.96 Mil. Tenax Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Tenax Therapeutics's net margin for the quarter that ended in Sep. 2024 was 0.00%.
The historical rank and industry rank for Tenax Therapeutics's Net Margin % or its related term are showing as below:
The historical data trend for Tenax Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenax Therapeutics Annual Data | |||||||||||||||||||||
Trend | Apr14 | Apr15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Net Margin % | Get a 7-Day Free Trial | - | - | - | - | - |
Tenax Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Net Margin % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Tenax Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Tenax Therapeutics's Net Margin % falls into.
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Tenax Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as
Net Margin | = | Net Income (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | -7.711 | / | 0 | |
= | % |
Tenax Therapeutics's Net Margin for the quarter that ended in Sep. 2024 is calculated as
Net Margin | = | Net Income (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | -3.96 | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenax Therapeutics (NAS:TENX) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of Tenax Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Robyn Hunter | director | 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453 |
Eliot M Lurier | officer: Interim CFO | C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
Chrisopher Thomas Giordano | director, officer: CEO | C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
Armistice Capital, Llc | director | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Armistice Capital Master Fund Ltd. | director | C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Steven Boyd | director | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
June Sherie Almenoff | director | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019 |
Michael H. Davidson | director | OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540 |
Declan Doogan | director | C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510 |
Stuart Rich | officer: Chief Medical Officer | C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
Illya Keith Maher | director | C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022 |
Ronald R Blanck | director | 2001 WALNUT HILL LANE, IRVING TX 75038 |
Gerald T Proehl | director | |
James P. Mitchum | director | C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709 |
John P Kelley | officer: Chief Executive Officer | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
From GuruFocus
By GuruFocus News • 11-14-2024
By sperokesalga sperokesalga • 05-31-2023
By PRNewswire PRNewswire • 02-02-2023
By GuruFocusNews GuruFocusNews • 01-12-2022
By Business Wire Business Wire • 10-06-2021
By PRNewswire • 02-12-2024
By Business Wire Business Wire • 09-28-2021
By Business Wire Business Wire • 03-30-2022
By Business Wire Business Wire • 05-23-2022
By Business Wire Business Wire • 05-25-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.